Table 1. Distribution of tumor mutational burden and ICB treatment by cancer type Since response to ICB was interrogated in these relationships, only the 490 treated patients were included in this analysis.
| Reported Mutations (n; %) | Treatment (n; %) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients (n, %) | 0–1 | 2–12 | >12 | ICB | Non-ICB | |||||||
| Cancer Type | ||||||||||||
| Colorectal Adenocarcinoma | 87 | 17.8 | 2 | 2.3 | 80 | 92.0 | 5 | 5.7 | 5 | 5.7 | 82 | 94.3 |
| Sarcoma, High Grade | 64 | 13.1 | 26 | 40.6 | 36 | 56.3 | 2 | 3.1 | 13 | 20.3 | 51 | 79.7 |
| Breast Carcinoma | 38 | 7.8 | 7 | 18.4 | 30 | 78.9 | 1 | 2.6 | 2 | 5.3 | 36 | 94.7 |
| Serous Carcinoma, High Grade | 37 | 7.6 | 10 | 27.0 | 27 | 73.0 | 0 | 0.0 | 0 | 0.0 | 37 | 100.0 |
| Non-Colorectal GI Carcinoma | 33 | 6.7 | 10 | 30.3 | 21 | 63.6 | 2 | 6.1 | 6 | 18.2 | 27 | 81.8 |
| Non-Small Cell Lung Carcinoma | 29 | 5.9 | 8 | 27.6 | 18 | 62.1 | 3 | 10.3 | 15 | 51.7 | 14 | 48.3 |
| Renal Cell Carcinoma | 28 | 5.7 | 8 | 28.6 | 20 | 71.4 | 0 | 0.0 | 16 | 57.1 | 12 | 42.9 |
| Thyroid carcinoma | 20 | 4.1 | 14 | 70.0 | 6 | 30.0 | 0 | 0.0 | 4 | 20.0 | 16 | 80.0 |
| Adenoid Cystic Carcinoma | 17 | 3.5 | 12 | 70.6 | 5 | 29.4 | 0 | 0.0 | 9 | 52.9 | 8 | 47.1 |
| Urothelial Carcinoma | 15 | 3.1 | 0 | 0.0 | 11 | 73.3 | 4 | 26.7 | 5 | 33.3 | 10 | 66.7 |
| Head & Neck Squamous | 12 | 2.4 | 1 | 8.3 | 10 | 83.3 | 1 | 8.3 | 4 | 33.3 | 8 | 66.7 |
| Prostate Adenocarcinoma | 12 | 2.4 | 4 | 33.3 | 7 | 58.3 | 1 | 8.3 | 3 | 25.0 | 9 | 75.0 |
| Glioma, High Grade | 9 | 1.8 | 2 | 22.2 | 5 | 55.6 | 2 | 22.2 | 0 | 0.0 | 9 | 100.0 |
| Endometrioid Carcinoma | 7 | 1.4 | 0 | 0.0 | 6 | 85.7 | 1 | 14.3 | 0 | 0.0 | 7 | 100.0 |
| Germ Cell Tumor | 5 | 1.0 | 0 | 0.0 | 5 | 100.0 | 0 | 0.0 | 0 | 0.0 | 5 | 100.0 |
| Other | 77 | 15.7 | 30 | 39.0 | 39 | 50.6 | 8 | 10.4 | 21 | 27.3 | 56 | 72.7 |
| Overall | 490 | 100 | 134 | 27.3 | 326 | 66.5 | 30 | 6.1 | 103 | 21.0 | 387 | 79.0 |